Rebecca Dent, MD, MSc, deputy chief executive officer and senior consultant at the National Cancer Center in Singapore, ...
KEYNOTE-B96 is the first trial to show overall survival (OS) improvement with an immune checkpoint inhibitor-based treatment ...
Stephen Freedland, MD, of Cedars-Sinai, discussed enzalutamide and leuprolide's potential to improve overall survival without ...
Roflumilast 0.05% cream, a phosphodiesterase 4 inhibitor, was approved by the FDA on October 6, having been specifically ...
Brensocatib effectively reduces NSP activity in bronchiectasis patients, with greater reductions observed in the 25-mg dose group compared to the 10-mg group.
Briers led off a group of speakers in an ESMO Quality of Life session on confronting sexual dysfunction after cancer care, which included a look at data from Europa UOMO on how treatment affects ...
Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, ...
In August, Zongertinib received FDA approval for previously treated HER2-mutant NSCLC. It now shows efficacy in first-line ...
Self-administration of rozanolixizumab, a neonatal Fc receptor blocker (FcRn) indicated for generalized myasthenia gravis, ...
Combining demands and control components in digital interventions significantly reduces burnout, anxiety, and emotional ...
Researchers identify FGFR4, FLT1, and WNT5A as key biomarkers and suggest dovitinib and nintedanib as new targeted therapies ...
The government should focus on keeping up the funding for HIV to continue to innovate in this space, potentially eliminating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results